Study of Investigational Antidepressant Therapy for Depression

If you participate in this study, you will be in the study for maximum up to 98 days including 4 weeks of the screening period. You will take AVP-786 capsules or identical placebo capsules (both are called “study medication”), twice daily, for about two and a half months (70 days). A placebo is a study medication look-alike, but contains no real medicine. You will be allowed to continue taking your usual medications for depression while you are participating in this study. For this study the current MDD episode should be less than or equal to 24 months in duration from screening. Patients have been deemed to have an inadequate response (< 50% symptom reduction) to at least 1 but no more than 3 adequate antidepressant trials during the current depressive episode. Patients must be receiving ongoing treatment with an adequate dose of only 1 antidepressant such as SSRIs (e.g., fluoxetine, sertraline, citalopram), SNRIs (e.g., venlafaxine, desvenlafaxine, duloxetine), bupropion, or other antidepressants for at least 6 weeks